COMT inhibitors: Novel treatments for Parkinson's disease

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Catechol-O-methyltransferase (COMT) inhibitors are a new class of medication being developed for the treatment of Parkinson's disease (PD). The enzyme COMT metabolizes levodopa and dopamine, both peripherally and centrally. Coadministration of a COMT inhibitor with levodopa creates an increase in peripheral and central levodopa bioavailability, as well as higher central dopamine concentrations. Because these actions improve the duration of response to levodopa, the COMT inhibitors should prove to be useful adjunctive therapies in PD patients.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalCNS Spectrums
Issue number2
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'COMT inhibitors: Novel treatments for Parkinson's disease'. Together they form a unique fingerprint.

Cite this